{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:38:53Z","timestamp":1777527533720,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,30]],"date-time":"2026-12-30T00:00:00Z","timestamp":1798588800000},"content-version":"am","delay-in-days":394,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R42GM131433"],"award-info":[{"award-number":["1R42GM131433"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpet.2025.103635","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:13:06Z","timestamp":1767082386000},"page":"103635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of equilibrative nucleoside transporters 1 and 2 by proteolysis-targeting chimeras (PROTACs)"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4015-6410","authenticated-orcid":false,"given":"Patricia A.","family":"Vignaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7509-4684","authenticated-orcid":false,"given":"Lucy J.","family":"Martinez Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-9442","authenticated-orcid":false,"given":"Renuka","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique O.","family":"Farrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5790","authenticated-orcid":false,"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jpet.2025.103635_bib1","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.jpet.2025.103635_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"9","key":"10.1016\/j.jpet.2025.103635_bib3","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1021\/acschembio.8b00692","article-title":"Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action","volume":"13","author":"Riching","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103635_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103635_bib5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/14756366.2022.2076675","article-title":"Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges","volume":"37","author":"Wang","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"4","key":"10.1016\/j.jpet.2025.103635_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2533\/chimia.2022.341","article-title":"Linkers as game-changers in PROTAC technology: emphasizing general trends in PROTAC pharmacokinetics for their rational design","volume":"76","author":"Cecchini","year":"2022","journal-title":"Chimia (Aarau)"},{"issue":"15","key":"10.1016\/j.jpet.2025.103635_bib7","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.jpet.2025.103635_bib8","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1021\/acs.jmedchem.3c02332","article-title":"Beyond rule of five and PROTACs in modern drug discovery: polarity reducers, chameleonicity, and the evolving physicochemical landscape","volume":"67","author":"Price","year":"2024","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.jpet.2025.103635_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103917","article-title":"Exploring the chemical space of orally bioavailable PROTACs","volume":"29","author":"Apprato","year":"2024","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.jpet.2025.103635_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib12030043","article-title":"Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier","volume":"12","author":"Tashima","year":"2023","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103635_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103387","article-title":"Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)","volume":"28","author":"Saraswat","year":"2023","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jpet.2025.103635_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103635_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acs.biochem.4c00577","article-title":"Journey of PROTAC: from bench to clinical trial and beyond","volume":"64","author":"Berkley","year":"2025","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.jpet.2025.103635_bib15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.chembiol.2020.04.003","article-title":"Targeted degradation of SLC transporters reveals amenability of multi-pass transmembrane proteins to ligand-induced proteolysis","volume":"27","author":"Bensimon","year":"2020","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103635_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jpet.2025.103635_bib17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/157016109789043892","article-title":"Nucleoside transporter proteins","volume":"7","author":"Molina-Arcas","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jpet.2025.103635_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215981","article-title":"ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer","volume":"552","author":"Mullen","year":"2023","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.jpet.2025.103635_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","article-title":"The equilibrative nucleoside transporter family, SLC29","volume":"447","author":"Baldwin","year":"2004","journal-title":"Pflugers Arch"},{"issue":"5","key":"10.1016\/j.jpet.2025.103635_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13318-021-00703-2","article-title":"Differential inhibition of equilibrative nucleoside transporter 1 (ENT1) activity by tyrosine kinase inhibitors","volume":"46","author":"Jouan","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jpet.2025.103635_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/jpet.112.191577","article-title":"Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K","volume":"341","author":"Astorga","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103635_bib22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.123.001979","article-title":"Characterization of human organic anion transporter 4 (hOAT4) and mouse Oat5 (mOat5) as functional orthologs for renal anion uptake and efflux transport","volume":"391","author":"Martinez-Guerrero","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103635_bib23","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1021\/acs.molpharmaceut.4c00984","article-title":"Computational approaches for predicting drug interactions with human organic anion transporter 4 (OAT4)","volume":"22","author":"Martinez-Guerrero","year":"2025","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.jpet.2025.103635_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/mol.116.105056","article-title":"Lack of influence of substrate on ligand interaction with the human multidrug and toxin extruder, MATE1","volume":"90","author":"Mart\u00ednez-Guerrero","year":"2016","journal-title":"Mol Pharmacol"},{"issue":"D1","key":"10.1016\/j.jpet.2025.103635_bib25","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103635_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acs.chas.2c00088","article-title":"Comparing LD50\/LC50 machine learning models for multiple species","volume":"30","author":"Lane","year":"2023","journal-title":"J Chem Health Saf"},{"issue":"10","key":"10.1016\/j.jpet.2025.103635_bib28","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acs.molpharmaceut.8b00083","article-title":"Comparing and validating machine learning models for Mycobacterium tuberculosis drug discovery","volume":"15","author":"Lane","year":"2018","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.jpet.2025.103635_bib29","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"10.1016\/j.jpet.2025.103635_bib30","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1039\/D0MD00382D","article-title":"Selective degradation-inducing probes for studying cereblon (CRBN) biology","volume":"12","author":"Powell","year":"2021","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.jpet.2025.103635_bib31","article-title":"Structure-activity relationship studies of 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) analogues as inhibitors of human equilibrative nucleoside transporters","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103635_bib32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.2002.03538.x","article-title":"In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia","volume":"117","author":"Galmarini","year":"2002","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.jpet.2025.103635_bib33","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","author":"Spratlin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103635_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pan.2024.01.009","article-title":"The prognostic and predictive role of class III \u03b2-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma","volume":"24","author":"Sahin","year":"2024","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.jpet.2025.103635_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"issue":"suppl 1","key":"10.1016\/j.jpet.2025.103635_bib36","doi-asserted-by":"crossref","first-page":"i42","DOI":"10.1093\/rheumatology\/kex433","article-title":"Novel uricosurics","volume":"57","author":"Bardin","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103635_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103635_bib38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00204-022-03428-6","article-title":"Perfluoroalkyl substances (PFASs) are substrates of the renal human organic anion transporter 4 (OAT4)","volume":"97","author":"Louisse","year":"2023","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jpet.2025.103635_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2024.142390","article-title":"Evaluation of 14 PFAS for permeability and organic anion transporter interactions: implications for renal clearance in humans","volume":"361","author":"Ryu","year":"2024","journal-title":"Chemosphere"},{"issue":"12","key":"10.1016\/j.jpet.2025.103635_bib40","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1124\/dmd.121.000803","article-title":"Human pharmacokinetics of LYS006, an oral leukotriene A4 hydrolase inhibitor displaying target-mediated drug disposition","volume":"50","author":"Poller","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.jpet.2025.103635_bib41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.xphs.2021.09.035","article-title":"Role of uptake transporters OAT4, OATP2A1, and OATP1A2 in human placental bio-disposition of pravastatin","volume":"111","author":"Fokina","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpet.2025.103635_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.10.002","article-title":"Substrate recognition of renally eliminated angiotensin II receptor blockers by organic anion transporter 4","volume":"36","author":"Noguchi","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1016\/j.jpet.2025.103635_bib43","first-page":"243","article-title":"Are we ready to design oral PROTACs?","volume":"9","author":"Jimenez","year":"2021","journal-title":"ADMET DMPK"},{"issue":"19","key":"10.1016\/j.jpet.2025.103635_bib44","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/acs.jmedchem.2c00201","article-title":"Designing soluble PROTACs: strategies and preliminary guidelines","volume":"65","author":"Garc\u00eda J\u00edmenez","year":"2022","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.jpet.2025.103635_bib45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/pharmaceutics16070846","article-title":"Conquering the beyond rule of five space with an optimized high-throughput Caco-2 assay to close gaps in absorption prediction","volume":"16","author":"Muschong","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpet.2025.103635_bib46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/CMAR.S465098","article-title":"Human equilibrative nucleoside transporter 1: novel biomarker and prognostic indicator for patients with gemcitabine-treated pancreatic cancer","volume":"16","author":"Xiao","year":"2024","journal-title":"Cancer Manag Res"},{"issue":"8","key":"10.1016\/j.jpet.2025.103635_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103643","article-title":"Industry perspective on the nonclinical safety assessment of heterobifunctional degraders","volume":"28","author":"Hemkens","year":"2023","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jpet.2025.103635_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54914-7","article-title":"Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief","volume":"15","author":"Wright","year":"2024","journal-title":"Nat Commun"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:33:28Z","timestamp":1777394008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022356525398484"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103635","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of equilibrative nucleoside transporters 1 and 2 by proteolysis-targeting chimeras (PROTACs)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103635"}}